Nafoxidine

Source: Wikipedia, the free encyclopedia.
Nafoxidine
Clinical data
Other namesU-11,000A; NSC-70735
Routes of
administration		By mouth
ATC code
  • None
Identifiers
  • 1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
JSmol)
  • COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5
  • InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
  • Key:JEYWNNAZDLFBFF-UHFFFAOYSA-N

Nafoxidine (

hair loss, and phototoxicity of the skin in almost all patients,[5] and this resulted in the discontinuation of its development.[4][7]

Nafoxidine is a long-acting

nuclear retention in the range of 24 to 48 hours or more.[8]

Comparison of early clinical experience with antiestrogens for advanced breast cancer
Antiestrogen Dosage Year(s) Response rate Adverse effects
Ethamoxytriphetol 500–4,500 mg/day 1960 25%
Acute psychotic episodes
Clomifene 100–300 mg/day 1964–1974 34% Risks of cataracts
Nafoxidine 180–240 mg/day 1976 31% Cataracts, ichthyosis, photophobia
Tamoxifen 20–40 mg/day 1971–1973 31% Transient thrombocytopeniaa
Footnotes: a = "The particular advantage of this drug is the low incidence of troublesome side effects (25)." "Side effects were usually trivial (26)." Sources: [9][10]

References

  1. ISBN 978-1-4757-2085-3
    .
  2. ^
    ISBN 978-1-59259-152-7
    .
  3. ISBN 978-3-319-13278-5
    .
  4. ^
    PMID 23810002
    .
  5. ^
    PMID 27889048
    .
  6. PMID 661750
    .
  7. ISBN 978-0-8493-5973-6
    .
  8. PMID 6277697
    .
  9. PMID 12796359
    .
  10. ISBN 978-1-84816-959-3
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nafoxidine&oldid=1188081296"